ArticleProtein science : a publication of the Protein Society2025
PSR-MAPMS: A new approach for the interpretable prediction of myelin autoantigenic peptides in multiple sclerosis using multi-source propensity scores.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MIF-MAPMS: Enhancing identification of myelin autoantigenic peptides in multiple sclerosis through multimodal information fusion.Protein science : a publication of the Protein Society · 2026Article
- Immune-gut-metabolite Interactions in Multiple Sclerosis: A Mendelian Randomization and Mediation Study.Current neurovascular research · 2026Article
- Leveraging a Meta-Learning Strategy to Advance the Accuracy of Neutralizing Antibodies against Dengue Virus Serotype Prediction.ACS omega · 2025Article
- Identifying protein succinylation sites using generative transformer and a two-dimensional representation with a deep capsule network.iScience · 2025Article
- PSR-MAPMS: A new approach for the interpretable prediction of myelin autoantigenic peptides in multiple sclerosis using multi-source propensity scores.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Within the central nervous system, the myelin sheath is composed of elements known as myelin autoantigens that are mistakenly targeted by the immune system in multiple sclerosis (MS). This autoimmune attack leads to the destruction of myelin, resulting in the neurological symptoms characteristic of MS. Identifying myelin autoantigenic peptides is crucial for understanding the pathogenesis of MS and developing targeted therapies. Traditional approaches often struggle with the complexity and heterogeneity of biological data, making it challenging to achieve accurate predictions in a cost-effective manner. Alternatively, computational approaches that utilize sequence information can aid in the biological elucidation of peptides. In this study, we present a novel propensity score-based approach, termed PSR-MAPMS, to predict and characterize T cell-specific myelin autoantigenic peptides in MS (MAPMSs). To the extent of our knowledge, PSR-MAPMS is the first machine learning (ML)-based approach that can predict and analyze MAPMSs based solely on sequence information. In PSR-MAPMS, we generated multiple aspects of propensity scores for MAPMSs. Important propensity scores were then chosen and applied to create the final hybrid model using an ensemble learning strategy. Extensive experiments results showed that PSR-MAPMS surpasses several conventional ML-based classifiers for MAPMS prediction in both cross-validation and independent tests. In the independent test results, the accuracy, MCC, and F1 scores of PSR-MAPMS were within the ranges of 0.899-0.949, 0.800-0.899, and 0.903-949, respectively. Moreover, our estimated propensity scores can identify crucial biochemical and physicochemical properties of MAPMSs, providing valuable revelations of the fundamental biological mechanisms, which facilitates the development of more effective and personalized treatments for MS. In addition, we created a simple-to-navigate web server for PSR-MAPMS, which is publicly accessible at https://pmlabqsar.pythonanywhere.com/PSR-MAPMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.